ArticleGeroScience2026
Accelerated biological aging is associated with faster multimorbidity progression: a UK biobank study.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study examined the associations of biological age accelerations (BAAs)-KDM-BA acceleration (via Klemera and Doubal's method) and PhenoAge acceleration (epigenetics-based), defined as residuals from regressing each biological age estimate on chronological age (CA)-with multimorbidity progression (measured by the Charlson Comorbidity Index, CCI), compared to CA. Utilizing UK Biobank data (n = 317,835; median follow-up: 13 years), Cox regression models adjusted for sex, ethnicity, lifestyle, and socioeconomic factors showed that each 1-year increase in KDM-BA acceleration raised the risk of CCI progression by 9.9% (HR [95% CI]: 1.099 [1.094-1.104]) and in PhenoAge acceleration by 4.3% (HR [95% CI]: 1.043 [1.041-1.044]). Consistent results were found in subgroup, sensitivity, and restricted cubic spline analyses, with PhenoAge acceleration achieving the highest predictive performance (C-index = 0.6755) compared to KDM-BA acceleration (0.6734) and CA (0.6701). These findings support the use of BAAs as cost-effective tools for assessing the risk of multimorbidity progression.
Indexed as
Identifiers
41945275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.